Χώρα: Καναδάς
Γλώσσα: Αγγλικά
Πηγή: Health Canada
FAMOTIDINE
BAKER CUMMINS INC
A02BA03
FAMOTIDINE
40MG
TABLET
FAMOTIDINE 40MG
ORAL
100
Prescription
HISTAMINE H2-ANTAGONISTS
Active ingredient group (AIG) number: 0118722002; AHFS:
CANCELLED PRE MARKET
2017-08-30
PRODUCT MONOGRAPH BCI FAMOTIDINE TABLETS (FAMOTIDINE TABLETS, USP) 20 MG AND 40 MG THERAPEUTIC CLASSIFICATION HISTAMINE H 2 RECEPTOR ANTAGONIST MANUFACTURER: IVAX PHARMACEUTICALS, INC. DATE OF PREPARATION: 4400 BISCAYNE BLVD., AUGUST 13, 2004 MIAMI, FLORIDA 33137 USA DISTRIBUTED BY: BAKER CUMMINS, INC. 1 PLACE VILLE-MARIE, SUITE 3900 MONTREAL, QUEBEC, CANADA H3B 4M7 CONTROL#: 093338 1 PRODUCT MONOGRAPH BCI FAMOTIDINE TABLETS (FAMOTIDINE TABLETS, USP) 20 MG AND 40 MG THERAPEUTIC CLASSIFICATION HISTAMINE H 2 RECEPTOR ANTAGONIST ACTION AND CLINICAL PHARMACOLOGY Famotidine is a competitive inhibitor of histamine H 2 -receptors. The primary clinically important pharmacologic activity of famotidine is inhibition of gastric juice secretion. Famotidine reduces the acid and pepsin content, as well as the volume of basal, nocturnal, and stimulated gastric secretion. COMPARATIVE BIOAVAILABILITY STUDIES A comparative bioavailability study was performed under fasting conditions using healthy human volunteers. The rate and extent of absorption of famotidine after a single oral 40 mg dose of BCI Famotidine 40 mg tablets or Pepcid® 40 mg tablets was measured and compared. A summary of the pharmacokinetic parameters is given in the table on the following page: 2 Famotidine (1 x 40 mg) From measured data Geometric Mean Arithmetic Mean (CV%) PARAMETER TEST BCI FAMOTIDINE TABLETS REFERENCE PEPCID® † % RATIO OF GEOMETRIC MEANS CONFIDENCE INTERVAL AUC T (ng.h/mL) 906.1 939.5 (27.4) 855.61 892.8 (30.5) 106 (98, 114) AUC I (ng.h/mL) 927.03 961.8 (27.7) 874.04 911.6 (30.4) 106 (98.3, 114) C MAX (ng/mL) 138.20 144.2 (29.2) 131.71 137.96 (31.6) 105 (95.8, 115) T MAX * (h) 2.7 (43.5) 2.65 (37.8) T ½ * (h) 4.38 (20.52) 4.43 (17.18) † Pepcid® is manufactured by Merck Frosst Canada and Company. Pepcid® was purchased in Canada. INDICATIONS AND CLINICAL USE BCI Famotidine Tablets are indicated in the treatment of the following conditions where a controlled reduction of gastric secretion is required: 1. Treatment of acute duodenal ulcer; Διαβάστε το πλήρες έγγραφο